RT-112 Xenograft Model Service for Bladder Cancer

The RT-112 Xenograft Model Service for Bladder Cancer provides a robust, FGFR3-driven luminal-like preclinical platform for evaluating novel therapeutic agents against urothelial carcinoma. Alfa Cytology delivers this specialized service with end-to-end model development, pharmacokinetic profiling, and efficacy assessment, enabling researchers to accelerate their bladder cancer drug discovery programs with confidence.

Overview of RT-112 Xenograft Model for Bladder Cancer

The RT-112 cell line was established in 1973 from a primary transitional cell carcinoma (histological grade G2) of the urinary bladder and has since become a cornerstone model for luminal-like bladder cancer research. Characterized by an FGFR3-TACC3 fusion and FGFR3 amplification, RT-112 represents the non-aggressive, papillary subtype of urothelial carcinoma, displaying high metabolic plasticity, potentiated respiratory and glycolytic machinery, and a pronounced propensity for three-dimensional spheroid formation. In xenograft settings, RT-112 tumors establish reliably in immunodeficient hosts---such as CB17/SCID mice and B-Rag2 knockout rats---exhibiting consistent growth kinetics and sustained FGFR3-driven signaling, making this model indispensable for preclinical evaluation of FGFR-targeted therapies, combination regimens, and metabolic intervention strategies.

Molecular profiling classifies RT-112 within the luminal-papillary cluster, co-expressing basal, luminal, and epithelial-mesenchymal transition markers in orthotopic xenograft contexts. The cell line demonstrates elevated ATP production through both oxidative phosphorylation and glycolysis, with substantial reserve capacity under metabolic stress, and shows limited migratory capacity compared to basal-like counterparts. These phenotypic and bioenergetic traits render the RT-112 xenograft model particularly suited for studying tumor maintenance, targeted inhibition of oncogenic drivers, and the interplay between metabolic dependencies and therapeutic response in low-grade bladder cancer.

Figure 1. Influence of AITC (A), PEITC (B), and BITC (B) on chemotactic movement of parental (Par),cisplatin-resistant (Cis) or gemcitabine-resistant (Gem) RT112, T24, and TCCSUP cells. (Rutz, J, et al., 2026)

Cell Line Information: RT-112

The RT-112 cell line is a well-characterized human bladder carcinoma line with extensive documentation in peer-reviewed literature. The following table summarizes its essential characteristics for preclinical model development.

Our Services

Alfa Cytology offers comprehensive RT-112 xenograft model services tailored to your preclinical research objectives, encompassing model establishment, in-life monitoring, pharmacodynamic analysis, and histopathological endpoints. Our experienced team ensures rigorous quality control, reproducible tumor growth, and seamless integration with downstream efficacy and safety assessments, providing you with reliable data to advance your bladder cancer therapeutic pipeline.

Workflow of RT-112 Xenograft Model Construction

The construction of the RT-112 xenograft model follows a standardized, quality-controlled workflow designed to ensure consistent tumor engraftment, robust growth kinetics, and reliable pharmacological readouts. Each stage is executed under strict ethical and scientific standards to deliver publication-ready preclinical data.

1. Cell Line Authentication and Expansion: RT-112 cells are authenticated via STR profiling and expanded under optimized culture conditions to ensure genetic stability and viability prior to inoculation.
2. Host Selection and Preparation: Immunodeficient hosts---typically CB17/SCID mice, NSG mice, or B-Rag2 KO rats---are acclimatized and health-screened to minimize environmental variability and ensure engraftment success.
3. Tumor Cell Inoculation: A suspension of 5 x 10^6 (mice) or 1 x 10^7 (rats) viable RT-112 cells, optionally mixed with Matrigel for enhanced take rates, is inoculated subcutaneously into the flank or orthotopically into the bladder wall depending on study design.
4. Tumor Monitoring and Randomization: Tumor volumes are measured twice weekly via caliper or non-invasive imaging; once tumors reach the target threshold volume (typically 100--150 mm^3), animals are randomized into treatment cohorts.
5. Treatment Administration and In-Life Assessment: Test compounds are administered according to the predefined dosing regimen, with concurrent monitoring of body weight, clinical signs, and tumor dimensions to evaluate tolerability and early efficacy signals.
6. Endpoint Analysis and Sample Collection: At study termination, tumors are excised, weighed, and processed for histopathology, immunohistochemistry, RNA sequencing, and biomarker analysis to generate comprehensive pharmacodynamic profiles.
7. Data Compilation and Reporting: All raw data, statistical analyses, and representative images are compiled into a structured study report, including tumor growth inhibition metrics, survival curves, and mechanistic insights for regulatory or publication use.

Figure 2. RT-112 xenograft model construction workflow.

Case Study-RT-112 Xenograft Model Development

In a representative preclinical engagement, the RT-112 xenograft model was successfully established in immunodeficient mice with a tumor take rate exceeding 90% and consistent growth kinetics suitable for multi-week efficacy studies. Treatment arms evaluating novel FGFR inhibitors and combination regimens demonstrated dose-dependent tumor growth inhibition, with select cohorts achieving significant tumor stasis or regression compared to vehicle controls. Comprehensive pharmacodynamic analyses---including immunohistochemical assessment of proliferation markers, FGFR pathway modulation, and metabolic profiling---provided mechanistic validation of target engagement. Detailed quantitative results, including tumor volume trajectories, body weight profiles, and biomarker data, are available upon request; please contact our scientific team to discuss specific study parameters and customize the model to your therapeutic program.

Why Choose Alfa Cytology?

Alfa Cytology combines scientific rigor with operational flexibility to deliver high-quality RT-112 xenograft model services that meet the exacting standards of modern preclinical oncology research.

• Extensive experience with FGFR3-driven luminal bladder cancer models and established SOPs for reproducible RT-112 tumor engraftment.
• Comprehensive in-house capabilities spanning model construction, in-life management, bioanalysis, histopathology, and molecular profiling.
• Customizable study designs accommodating single-agent, combination, dose-escalation, and biomarker-driven endpoints tailored to your compound.
• Strict quality assurance including cell line authentication, health monitoring, and GLP-compliant data documentation for regulatory submissions.
• Dedicated project management ensuring transparent communication, milestone tracking, and rapid turnaround from study initiation to final report.
• Competitive pricing and flexible scheduling to accelerate your preclinical timeline without compromising scientific integrity.

Contact Us

Ready to advance your bladder cancer therapeutic program with a validated RT-112 xenograft model? Contact us or reach out to our preclinical specialists today to discuss your study requirements, receive a customized proposal, and explore how Alfa Cytology can accelerate your path from discovery to development. Our team is committed to delivering reliable, actionable data that drives confident decision-making in your oncology pipeline. Please reach out to us today via our inquiry form or email to learn more about our RT-112 Xenograft Model services.

For research use only. Not intended for any clinical use.